From Basic Science to Clinical Research to Develop New Solutions to Improve Diagnoses and Treatment of Bladder Cancer Patients

Moschini, Marco

doi:10.3390/jcm9082373

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BC is among the ten leading causes of cancer-related deaths worldwide [ 1 ] and account for 3% of new cancer cases worldwide in 2020 [ 2 ]. The main therapeutic approaches for BC include chemotherapy and surgery; even with radical surgery, the five-year overall survival (OS) rate is 70%.…”

Section: Introductionmentioning

confidence: 99%

Integrated Analysis and Identification of Critical RNA-Binding Proteins in Bladder Cancer

Chen

et al. 2022

Cancers

View full text Add to dashboard Cite

RBPs in the development and progression of bladder cancer (BC) remains unclear. Here, we elucidated the role of RBPs in predicting the survival of patients with BC. Clinical information and RNA sequencing data of the training and validation cohorts were downloaded from the Cancer Genome Atlas and Gene Expression Omnibus databases, respectively. Survival-related differentially expressed RBPs were identified using Cox regression analyses. A total of 113 upregulated and 54 downregulated RBPs were observed, with six showing prognostic values (AHNAK, MAP1B, LAMA2, P4HB, FASN, and GSDMB). In both the GSE32548 and GSE31684 datasets, patients with low-risk scores showed longer overall survival than those with high-risk scores. AHNAK, MAP1B, P4HB, and FASN expression were significantly upregulated in both BC tissues and cell lines. BC tissues from the high-risk group showed higher proportions of naïve CD4+ T cells, macrophages M0 and M2, and neutrophils and lower proportions of plasma cells, CD8+ T cells, and T-cell follicular helper compared to the low-risk group. AHNAK knockdown significantly inhibited the proliferation, invasion, and migration of BC cells in vitro and inhibited the formation and growth of subcutaneous tumors in vivo. We thus developed and functionally validated a novel six-RBP-based prognostic model for BC.

show abstract

Section: Introductionmentioning

confidence: 99%

Integrated Analysis and Identification of Critical RNA-Binding Proteins in Bladder Cancer

Chen

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

From Basic Science to Clinical Research to Develop New Solutions to Improve Diagnoses and Treatment of Bladder Cancer Patients

Abstract: Bladder cancer (BCa) is the tenth most common form of cancer worldwide, with 549,000 new cases and 200,000 deaths estimated in 2018 [...]

Cited by 1 publication

References 16 publications

Integrated Analysis and Identification of Critical RNA-Binding Proteins in Bladder Cancer

Integrated Analysis and Identification of Critical RNA-Binding Proteins in Bladder Cancer

Contact Info

Product

Resources

About